This Article Order Full text via Infotrieve Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Emery, R. W. Articles by Nicoloff, D. M. Search for Related Content PubMed PubMed Citation Articles by Emery, R. W. Articles by Nicoloff, D. M.

Circulation, Vol 60, 48-54, Copyright © 1979 by American Heart Association

ARTICLES

A new cardiac prosthesis: the St. Jude Medical cardiac valve: in vivo results

RW Emery, E Mettler and DM Nicoloff

The St. Jude Medical cardiac valve prosthesis is a low profile, lightweight, bi-leaflet, central-flow device constructed entirely of pyrolytic carbon. In vivo testing was performed in 24 cows in which the tricuspid valve (n = 14) or mitral valve (n = 10) was replaced by a St. Jude Medical prosthesis with a 26 mm tissue annulus diameter. Eight animals died in the operative period. The 16 surviving animals were sacrificed at 4, 8, 12, or 18 weeks. There were no valve-related deaths nor mechanical valve failures. Anticoagulation was not used in the postoperative period during which time monthly laboratory parameters were obtained including hemoglobin, hematocrit, white cell count, red cell count and indices, lactic acid dehydrogenase, serum haptoglobin, and, additionally at sacrifice, platelet and red cell morphology. Values indicated this prosthesis did not cause hemolysis. At sacrifice the pulmonary arterial tree and peripheral organs showed no evidence of thromboemboli. There was smooth endocardial ingrowth on all valve sewing rings. One valve had thrombus formation on the valve sewing ring. Nine animals were anesthetized prior to sacrifice and underwent open cardiac catheterization. Ventriculography (n = 6) showed minimal transvalvar reflux, and atriograms (n = 6) demonstrated central flow. Transvalvar gradients were 0 to 22 mm Hg (n = 9). One valve of an 18- week tricuspid implant was examined for wear; valve life was calculated to be greater than 2500 years. These data in conjunction with in vitro test results justify clinical trial of the St. Jude Medical prosthesis.

This article has been cited by other articles:

				R. W. Emery, C. C. Krogh, K. V. Arom, A. M. Emery, K. Benyo-Albrecht, L. D. Joyce, and D. M. Nicoloff The St. Jude Medical Cardiac Valve Prosthesis: A 25-Year Experience With Single Valve Replacement Ann. Thorac. Surg., March 1, 2005; 79(3): 776 - 782. [Abstract] [Full Text] [PDF]

				Y. Wu, R. Gregorio, A. Renzulli, F. Onorati, M. De Feo, G. Grunkemeier, and M. Cotrufo Mechanical heart valves: Are two leaflets better than one? J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1171 - 1179. [Abstract] [Full Text] [PDF]

				B. A. Carabello Aortic Regurgitation in Women: Does the Measuring Stick Need a Change? Circulation, November 15, 1996; 94(10): 2355 - 2357. [Full Text]

				E. Klodas, M. Enriquez-Sarano, A. J. Tajik, C. J. Mullany, K. R. Bailey, and J. B. Seward Surgery for Aortic Regurgitation in Women: Contrasting Indications and Outcomes Compared With Men Circulation, November 15, 1996; 94(10): 2472 - 2478. [Abstract] [Full Text]

				J. Bartunek, S. U. Sys, A. C. Rodrigues, E. Van Schuerbeeck, L. Mortier, and B. de Bruyne Abnormal Systolic Intraventricular Flow Velocities After Valve Replacement for Aortic Stenosis : Mechanisms, Predictive Factors, and Prognostic Significance Circulation, February 15, 1996; 93(4): 712 - 719. [Abstract] [Full Text]